Marx, W., McCarthy, A.L., Ried, K., McKavanagh, D., Vitetta, L., Sali, A., . . . Isenring, E. (2017). The effect of a standardized ginger extract on chemotherapy-induced nausea-related quality of life in patients undergoing moderately or highly emetogenic chemotherapy: A double blind, randomized, placebo controlled trial. Nutrients, 9, 867.
To determine if the addition of a standard dose ginger supplement to a standard antiemetic protocol for moderately to highly emetogenic chemotherapy in patients who were chemotherapy naïve reduced the incidence of CINV and positively affected quality of life. Secondarily, to determine the effect on fatigue and malnutrition in these same study patients
The study group received 1.2 g of ginger extract in addition to standard unspecified antiemetics while the control group was given a placebo. The ginger or placebo was taken in divided doses four times per day for five days starting the day of chemotherapy and four days after for three cycles. Both the ginger and the placebo were in similar capsule forms.
PHASE OF CARE: Active anti-tumor treatment
Double blinded, randomized, placebo controlled trial
Functional Living Index Emesis 5 Day Recall (FLIE-5DR), Rhodes Inventory of Nausea, Vomiting, and Retching (INVR), Patient-Generated Subjective Global (FACT-G) assessed nutrition; Functional Assessment of Cancer Therapy-Global (FACT-G) assessed fatigue and QOL; Functional Assessment of Chronic Illness Therapy-Fatigue (FACTIT-F) and an assessment of factors that are known to increase the risk of CINV; symptom assessment using the Edmonton Symptom Assessment Scale to determine any adverse reactions to the ginger/placebo.
The group receiving ginger had better nausea-related QOL and better total CINV-related QOL, less fatigue, and better overall cancer-related QOL, although clinical significance was minimal. There was no significant improvement in CINV occurrence or intensity.
Ginger had some benefits, including better nausea-related quality of life and better total CINV-related quality of life as well as less fatigue. The overall clinical significance of these findings is minimal. No significant improvement in CINV occurrence or intensity was noted.
There was no indication as to the cost or availability of this ginger extract, which may affect relevance. Also many assessment tools were used which questions validity. This manuscript suggests that ginger may be effective on nausea-related quality of life and fatigue, but a larger study would need to be done to confirm these findings.
Li, X., Qin, Y., Liu, W., Zhou, X.Y., Li, Y.N., & Wang, L.Y. (2018). Efficacy of ginger in ameliorating acute and delayed chemotherapy-induced nausea and vomiting among patients with lung cancer receiving cisplatin-based regimens: A randomized controlled trial. Integrative Cancer Therapies, 17, 747–754.
To determine the effectiveness of a standardized low-dose ginger supplement in addition to standard antiemetic therapy decreased the incidence of acute and delayed CINV in patients with lung cancer receiving chemotherapy regimens containing cisplatin
Patient randomly allocated to receive ginger root powder taken orally in the dose of 250 mg twice daily for five days starting 30 minutes prior to the start of chemotherapy or identical placebo in addition to standard antiemetics therapy (5HT3 RA)
PHASE OF CARE: Active anti-tumor treatment
Randomized, double-blind, placebo controlled
Multinational Association of Supportive Care in Cancer (MASCC) antiemesis tool; Functional Assessment of Cancer Therapy-General (QOL)
There was no significant difference between the intervention group and the control group in the incidence and severity of acute and delayed CINV or quality of life.
The use of a standardized ginger product with standardized antiemetic protocols produced no additional benefit in improving the incidence and severity of CINV in patients with lung cancer receiving chemotherapy regimens containing cisplatin.
Although nurses have historically recommended ginger-containing products to relieve nausea, a standardized dose of ginger extract demonstrated no efficacy.
Konmun, J., Danwilai, K., Ngamphaiboon, N., Sripanidkulchai, B., Sookprasert, A., & Subongkot, S. (2017). A phase II randomized double-blind placebo-controlled study of 6-gingerol as an anti-emetic in solid tumor patients receiving moderately to highly emetogenic chemotherapy. Medical Oncology, 34, 69.
To determine the effectiveness of standardized bioactive compound of ginger extract (6-Gingerol) on CINV in solid tumor patients receiving MEC to HEC in addition to standard antiemetics (ondansetron, metoclopramide, and dexamethasone) in solid tumor patients
Patients were randomized to receive 10 mg ginger extract capsule (6-gingerol) or a matching placebo twice daily three days before prior to chemotherapy to D1 and continued for 12 weeks; in addition to standard antiemetics. For HEC regimen, D1 (ondansetron 8 mg IV plus dexamethasone 12 mg IV) and oral daily on days 2 to 4. For MEC regimen, D1 (ondansetron 8 mg IV plus dexamethasone 8 mg IV) and oral daily on days 2 to 4. All patients received metoclopramide 10 mg orally three times daily on days 2 to 4. Rescue antiemetics were allowed at any time. Intensity of nausea and appetite was measured daily by the numeric rating scale. Also, patients recorded nausea and vomiting events daily from day 0 to 120 hours after each chemotherapy cycle. QOL measured by (FACT-G) instrument at days 1, 22, 43, and 64 of treatment.
Multicenter randomized, double-blind, placebo-controlled phase II study
Intensity of nausea and appetite was measured daily by the numeric rating scale using the Edmonton Symptom Assessment Scale (ESAS), ranging from 0 to 10. Quality of life will be measured by using version 4 of the Functional Assessment of Cancer Therapy-General (FACT-G). Daily diary from days 1-5 in each chemotherapy cycle (this includes number of vomiting episodes, nausea score, appetite score, QOL, use of rescue antiemetic, and hospitalization).
The overall CR rate was significantly higher in patients treated with 6-gingerol compared with placebo (p = 0.001) in both acute (p = 0.003) and delayed (p = 0.001) phases. However, during the first chemotherapy cycle, there was no statistically significant differences. Patient received 6-gingerol reported improvement in appetite (p = 0.001) and less severity of overall nausea p < 0.001 and statistical improvement in QOL (p < 0.001) compared to placebo. Ginger was well tolerated with no observed adverse effect.
Prolonged and continuous daily dosing of 6-gingerol appears to be effective. 6-gingerol improved patient’s appetite and QOL; it is safe and well tolerable
Ginger is safe and well tolerable complementary therapy for patient on MEC-HEC. It also improve patient appetite and QOL.
Bossi, P., Cortinovis, D., Fatigoni, S., Cossu Rocca, M., Fabi, A., Seminara, P., . . . Roila, F. (2017). A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Annals of Oncology, 28, 2547–2551.
To determine the effectiveness of ginger on the incidence and intensity of delayed nausea for patients on HEC (cisplatin)
Patients scheduled to receive high-dose cisplatin for two or more chemotherapy cycles were randomized to receive standardized ginger preparation 120 mg per day [two capsules of 40 mg twice daily] (16 mg gingerols plus 1.12 mg shogaoil) or placebo in addition to standard antiemetics (NK1 RA and 5-HT3 RA on day 1 and dexamethasone on days 1-4) for a period of two chemotherapy cycles; nearly 45 days.
Randomized, double-blind, placebo-controlled
Visual analog scale, 0–100 mm for nausea incidence and intensity, Functional Living Index Emesis (impact of nausea am daily living), Brief Fatigue Inventory questionnaire (impact of fatigue)
No significant differences between the two groups in relation to incidence of delayed nausea, intercycle nausea, and anticipatory nausea during the first and second cycle. In ginger group; men with lung cancer experienced a higher incidence of significant delayed and intercycle nausea (p < 0.05), incidence of delayed nausea was higher among patients with lung cancer in the ginger group than placebo (p = 0.042), no differences in FLIE and BFI between the two groups; a benefit of ginger over placebo in terms of FLIE for female versus male patients and in head/neck cancer versus lung cancer. No differences in experienced adverse effects between the two groups.
Ginger had no beneficial effect in reducing CINV (delayed, anticipatory, and intercycle) associated with HEC.
Daily ginger is safe; some patient might experience an increase in gastrointestinal symptoms.
Schussel, V., Kenzo, L., Santos, A., Bueno, J., Yoshimura, E., de Oliveira Cruz Latorraca, C., . . . Riera, R. (2017). Cannabinoids for nausea and vomiting related to chemotherapy: Overview of systematic reviews. Phytotherapy Research, 32, 567–576.
STUDY PURPOSE: To present the findings and conduct a critical appraisal of systematic reviews focusing on the effects of cannabinoids as a treatment for nausea and vomiting in patients with cancer during chemotherapy.
TYPE OF STUDY: Meta analysis and systematic review
DATABASES USED: EMBASE, PEDro, CINAHL, Cochrane Database of Systematic Reviews, LILACS, Medline, PsycINFO
YEARS INCLUDED: 2001 to 2015
INCLUSION CRITERIA: RCTs only, SRs focusing exclusively on cannabinoids for the treatment of CINV
EXCLUSION CRITERIA: Studies registered in PROSPERO and not completed or published by the date of search
TOTAL REFERENCES RETRIEVED: 2,206
EVALUATION METHOD AND COMMENTS ON LITERATURE USED: AMSTAR and PRISMA. Average AMSTAR score was 5, with low of 1 and high of 11. Max score of 11. Average PRISMA score was 13.2, ranging from 1 to 25. Max score of 27.
FINAL NUMBER STUDIES INCLUDED: 5
TOTAL PATIENTS INCLUDED IN REVIEW: Not included
KEY SAMPLE CHARACTERISTICS: Participants presenting nausea and/or vomiting attributed to any type of chemotherapy for cancer. Treatment included: THC, nabilone, dronabinol, and levonantradol compared to any pharmacologic or nonpharmacologic intervention.
PHASE OF CARE: Not specified or not applicable
Cannabinoids seem to be superior to placebo and equal to prochlorperazine in reducing nausea and vomiting, and, in general, are similar to standard antiemetics alone or in combination. Patient-reported outcomes indicated that patients tend to prefer cannabinoids over placebo and other antiemetics, but cannabinoids have a higher rate of adverse events when compared to traditional antiemetics.
Cannabinoids may be considered a therapeutic option for treating CINV. However, it is unclear from this analysis where cannabinoids are superior to traditional antiemetics in effectiveness or safety. There is a shortage of high-quality evidence to clarify these questions.
Cannabinoids may be effective and superior to placebo to treat CINV. Although adverse events were more frequent in patients treated with cannibinoids, patients preferred cannibinoids over other antiemetics. More studies are needed to evaluate the effectiveness and safety of cannabinoids in CINV.
Tamura, K., Aiba, K., Saeki, T., Nakanishi, Y., Kamura, T., Baba, H., . . . CINV Study Group of Japan. (2015). Testing the effectiveness of antiemetic guidelines: Results of a prospective registry by the CINV Study Group of Japan. International Journal of Clinical Oncology, 20, 855–865.
Patients were provided with seven-day diaries before the start of therapy with either highly emetogenic or moderately emetogenic chemotherapy. The patient must be receiving this type of therapy for the first time. Recording of digestive symptoms including severity of nausea, oral intake, and vomiting were measured using a visual analog scale. Investigators/colleagues recorded background information including date of birth, treatment history, use of anxiolytics, and use of opioids. Other risk factors including alcohol use, history of motion sickness or morning sickness, performance status, chemotherapy regimen, and clinical lab reports were collected in a case report, corresponding to the patient’s diary.
This was a multicenter prospective cohort study, including university hospitals, cancer centers, and cancer treatment centers. One hundred eight institutions throughout Japan participated.
Diaries and visual analog scales have long been utilized in CINV research, although several other instruments are available and reliable. Descriptive statistics were used as were univariate analysis and multivariate analysis (Wald's test) to evaluate risk factors for both acute and delayed nausea, and acute and vomiting. Fisher’s exact test was used to measure differences of occurrence between risk factors and HEC, MEC types of chemotherapy. There was no mention how providers gauged emetogenic risk for the patients, so it was difficult to tell if this was using a reliable instrument.
Multiple cancers and multiple chemotherapy regimens were evaluated. Acute nausea and vomiting with HEC was 20.8% and 5.7%; with MEC, it was 6.7% and 1.7%, respectively. There was a high incidence of delayed nausea, 49.4% with HEC, and 41.7% with MEC. Delayed vomiting was low at 11.2% with HEC and 15.9% with MEC, which was notably higher; however, if the patient received a three-drug antiemetic regimen, it was then significantly lower. Motion sickness was associated with a higher risk for acute nausea, with men being more susceptible than women. A history of morning sickness was also a risk factor in women. HEC was associated with the highest risk in both genders. Prophylactic use of three drug regimens was associated with reduced risk in men. Risk factor analysis also revealed that women were more susceptible to CINV in every aspect. Estimation of CINV by providers overestimated emetogenic risk.
A high compliance with guidelines was associated with a decreased incidence of CINV, particularly in the MEC group receiving three drugs. The authors recommend to study CINV for at least seven days. Mechanisms of acute CINV require further study to develop newer agents to target this symptom
Implications for nurses indicates that knowledge and adherence to guidelines assist in managing CINV. As nurses, we must be advocates for patients, and ensure that the patient receives the best supportive care to prevent CINV and avoid breakthrough symptoms. Nurses should be aware of ONS guidelines to guide their practice.
Patil, V.M., Noronha, V., Joshi, A., Ramaswamy, A., Gupta, S., Sahu, A., . . . Prabhash, K. (2017). Adherence to and implementation of ASCO antiemetic guidelines in routine practice in a tertiary cancer center in India. Journal of Oncology Practice, 13, e574–e581.
To evaluate adherence to ASCO guidelines and to improve quality of antiemetic prescriptions.
An initial audit of 1,211 consecutive prescriptions for adult patients with solid tumors receiving outpatient chemotherapy were characterized based on consistency with ASCO guidelines.
If a patient vomited, they were classified as having CINV if this occurred within five days after completion of chemotherapy and there was no other causation. Education was offered to clinicians regarding results of the audit. Review of the antiemetic policy was revised according to ASCO guidelines. A second audit occurred and included 201 patients.
Retrospective study
Measuring incidence of vomiting, emergency visits, and hospitalizations using Descriptive statistics and Fisher exact test
Patient incidence of CINV with adherence to guidelines had a lower rate of vomiting, 6.6% versus 21.9% (p < 0.001), emergency visits, 2.6% versus 5.8%, p = 0.006 and hospitalization for emesis, 0.9% versus 4.9%, p < 0.001. In ASCO adherent guidelines, the proportion of prescriptions at initial audit was 63.6% and at reassessment was 98.5% (p < 0.001). Proportion of overuse was 41.3% at re-audit, and 68.3% before the intervention (p = 0.001). Post-audit intervention included education of providers regarding guideline and policy.
Use of guidelines enhances patient outcomes by significantly reducing the occurrence of CINV. Use of semi-rigid corrective actions lead to substantial improvement in adherence rates at this institution. This study demonstrates the importance of using guidelines in clinical care.
Nazari, M., Taghizadeh, A., Bazzaz, M. M., Rakhshandeh, H., & Shokri, S. (2017). Effect of Persian medicine remedy on chemotherapy induced nausea and vomiting in breast cancer: A double blind, randomized, crossover clinical trial. Electronic Physician, 9, 3535–3543.
To assess the effects of Persumac, a Persian herbal preparation, on refractory CINV.
Patients were randomized to two study sequence groups. One group received Persumac first and then placebo in crossover. The other group received the opposite sequence. Patients were entered in the second course of chemotherapy. Crossover was done in the third course of chemotherapy. Persumac and placebo were taken three times daily before meals. A washout period of six days was done prior to the third chemotherapy course. Patients were studied for 33 days. Patients recorded information about the severity and number of nausea and vomiting episodes on a visual analog scale and answered questions related to frequency of forgetting to take the study drug or other antiemetics. All patients received standard triple antiemetic regimens. Persuma included sumac and Bunium persicum.
PHASE OF CARE: Active anti-tumor treatment
Double blind, randomized, crossover clinical trial
VAS for nausea and vomiting (1-10 scale)
Average nausea severity was significantly lower during the period when using the persumac (p < 0.001), with reduction in at least two points on the VAS in the delayed phase compared to baseline results. There was no significant effect for acute phase CINV. The number of vomiting episodes was reduced. There were very few patients who had complete response for CINV (range = 0%-23%)
Persumac appeared to have some benefit in reduction of the severity of delayed CINV in this study.
Findings suggest that the Persian herbal medicine, Persumac, may have some benefit in reducing delayed CINV in women receiving moderate to severe emetic chemotherapy. Further evidence is needed to determine potential benefit.
Miao, J., Liu, X., Wu, C., Kong, H., Xie, W., & Liu, K. (2017). Effects of acupressure on chemotherapy-induced nausea and vomiting-a systematic review with meta-analyses and trial sequential analysis of randomized controlled trials. International Journal of Nursing Studies, 70, 27–37.
STUDY PURPOSE: Assess effectiveness of acupressure on chemotherapy-induced nausea and vomiting (CINV)
TYPE OF STUDY: Meta-analysis and systematic review
PHASE OF CARE: Active anti-tumor treatment
Relative risk for incidence of acute vomiting across five trials was 0.84 in favor of acupressure, but this was not significant (p = 0.08). There was not a significant difference in relative risk with or without acupressure (p = 0.29) (two trials). Acupressure combined with antiemetics decreased nausea severity in the delayed phase (SMD = -0.33, p = 0.04), but there was no significant effect on incidence and frequency of delayed vomiting. P6 was the most frequently used acupoint. Interventions used either a wristband or manual acupressure, and findings for these two approaches differed. Sham control trials did not demonstrate a significant effect.
Acupressure may reduce the severity of nausea, particularly in the delayed phase in patients receiving MEC or HEC
Acupressure might be a useful adjunct to antiemetics for management of CINV. Findings suggest that this may be helpful to reduce the severity of nausea, which has remained a problem even with maximum antiemetics. Findings of this analysis showed differences with sham controlled trials, suggesting there may be a placebo effect of acupressure.
Yokota, T., Ogawa, T., Takahashi, S., Okami, K., Fujii, T., Tanaka, K., . . . Naka, Y. (2017). Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study. BMC Cancer, 17, 314.
Recent preclinical and phase I studies have reported that rebamipide decreased the severity of chemoradiotherapy-induced oral mucositis in patients with oral cancer. This placebo-controlled randomized phase II study assessed the clinical benefit of rebamipide in reducing the incidence of severe chemoradiotherapy-induced oral mucositis in patients with head and neck cancer (HNC).
Patients aged 20–75 years with HNC who were scheduled to receive chemoradiotherapy were enrolled. Patients were randomized to receive rebamipide 2% liquid, rebamipide 4% liquid, or placebo. The primary endpoint was the incidence of grade ≥ 3 oral mucositis determined by clinical examination and assessed by central review according to the Common Terminology Criteria of Adverse Events, version 3.0. Secondary endpoints were the time to onset of grade ≥ 3 oral mucositis and the incidence of functional impairment (grade ≥ 3) based on the evaluation by the Oral Mucositis Evaluation Committee.
Patients aged 20–75 years with HNC who were scheduled to receive chemoradiotherapy were enrolled. Patients were randomized to receive rebamipide 2% liquid, rebamipide 4% liquid, or placebo.
The incidence of oral mucositis in each group was compared using the chi-square test. A step-down strategy was used for the between-group comparison, adjusting for multiplicity. Comparisons were made first between the rebamipide 4% and the placebo groups, and then between the rebamipide 2% and placebo groups. The Cochran-Armitage test was used as a trend test. All statistical analyses were performed using SAS, version 9.2.
In a trend test, a decrease in the incidence of grade ≥ 3 oral mucositis was observed with an increasing concentration of rebamipide liquid; however, this decrease was not statistically significant (p = 0.2399).
The rebamipide 2% and 4% groups showed a trend of delaying the time to onset of grade ≥ 3 oral mucositis as compared with the placebo group, although the difference between the groups was not statistically significant
A decrease in incidence of grade ≥ 3 oral mucositis in patients treated with rebamipide 2% and 4% compared with those treated with placebo, these differences were not statistically significant.
There was a prolongation in the time to onset of grade ≥ 3 oral mucositis and a decrease in functional impairment in patients treated with rebamipide 4% compared to those treated with placebo; these results may suggest a clinical benefit of rebamipide in reducing the incidence of severe oral mucositis induced by CRT.
Systemic oral care alone is insufficient to decrease the incidence of severe oral mucositis. Therefore, there is a strong demand for the development of prophylactic and therapeutic agents against oral mucositis. There is efficacy and safety profiles that suggest rebamipide 4% is safe and effective, although not statistically significant. Further studies are needed using rebamipide 4% for treatment of CRT-induced oral mucositis.